Figure 3.
Impact of LSC17 in NPM1-mutated AML. (A) Impact of LSC17 status on OS from diagnosis per NPM1 status (N = 504). (B) Volcano plot of the association between baseline genetic factors on the LSC17 score in patients with NPM1-mutated AML (n = 187). The x-axis represents the difference between mean values of LSC17 scores in patients with or without the variable of interest. The y-axis represents the significance of the Wilcoxon test comparing the 2 groups, adjusting for multiple testing with the Benjamini-Hochberg method (dashed line corresponding to 0.05). Red and blue circles indicate cytogenetic and gene mutations variables, respectively; size is correlated with number of patients with the variable of interest. (C) Impact of LSC17 status (LSC17 high, red; LSC17 low, blue) and MRD status (negative, solid line; positive, dotted line) on OS from CR/CRp in NPM1-mutated AML (n = 123).

Impact of LSC17 in NPM1-mutated AML. (A) Impact of LSC17 status on OS from diagnosis per NPM1 status (N = 504). (B) Volcano plot of the association between baseline genetic factors on the LSC17 score in patients with NPM1-mutated AML (n = 187). The x-axis represents the difference between mean values of LSC17 scores in patients with or without the variable of interest. The y-axis represents the significance of the Wilcoxon test comparing the 2 groups, adjusting for multiple testing with the Benjamini-Hochberg method (dashed line corresponding to 0.05). Red and blue circles indicate cytogenetic and gene mutations variables, respectively; size is correlated with number of patients with the variable of interest. (C) Impact of LSC17 status (LSC17 high, red; LSC17 low, blue) and MRD status (negative, solid line; positive, dotted line) on OS from CR/CRp in NPM1-mutated AML (n = 123).

Close Modal

or Create an Account

Close Modal
Close Modal